{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:50:51Z","timestamp":1776408651982,"version":"3.51.2"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06881-w","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T08:29:45Z","timestamp":1771489785000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The optimal conditioning intensity of stem cell transplantation for acute myeloid leukemia in complete remission"],"prefix":"10.1007","volume":"105","author":[{"given":"Yoshimitsu","family":"Shimomura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Komukai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuhisa","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomotaka","family":"Sobue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadakazu","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaito","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Shingai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatsugu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumu","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Ohigashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichi","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Onizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiro","family":"Kawakita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Hiramoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masamitsu","family":"Yanada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"6881_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","volume":"127","author":"JJ Cornelissen","year":"2016","unstructured":"Cornelissen JJ, Blaise D (2016) Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood 127:62\u201370. https:\/\/doi.org\/10.1182\/blood-2015-07-604546","journal-title":"Blood"},{"key":"6881_CR2","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3324\/haematol.2015.123331","volume":"100","author":"S Sengsayadeth","year":"2015","unstructured":"Sengsayadeth S, Savani BN, Blaise D et al (2015) Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the acute leukemia working party of the EBMT. Haematologica 100:859\u2013869. https:\/\/doi.org\/10.3324\/haematol.2015.123331","journal-title":"Haematologica"},{"key":"6881_CR3","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1200\/JCO.2008.20.9692","volume":"27","author":"O Ringd\u00e9n","year":"2009","unstructured":"Ringd\u00e9n O, Labopin M, Ehninger G et al (2009) Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol Off J Am Soc Clin Oncol 27:4570\u20134577. https:\/\/doi.org\/10.1200\/JCO.2008.20.9692","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"6881_CR4","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1038\/sj.leu.2403967","volume":"19","author":"M Aoudjhane","year":"2005","unstructured":"Aoudjhane M, Labopin M, Gorin NC et al (2005) Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic Haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the acute leukemia working party (ALWP) of the European group for blood and marrow transplantation (EBMT). Leukemia 19:2304\u20132312. https:\/\/doi.org\/10.1038\/sj.leu.2403967","journal-title":"Leukemia"},{"key":"6881_CR5","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/S1470-2045(12)70349-2","volume":"13","author":"M Bornh\u00e4user","year":"2012","unstructured":"Bornh\u00e4user M, Kienast J, Trenschel R et al (2012) Reduced-intensity conditioning versus standard conditioning before allogeneic Haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol 13:1035\u20131044. https:\/\/doi.org\/10.1016\/S1470-2045(12)70349-2","journal-title":"Lancet Oncol"},{"key":"6881_CR6","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1200\/JCO.2016.70.7349","volume":"35","author":"N Kr\u00f6ger","year":"2017","unstructured":"Kr\u00f6ger N, Iacobelli S, Franke G-N et al (2017) Dose-Reduced versus standard conditioning followed by allogeneic Stem-Cell transplantation for patients with myelodysplastic syndrome: A prospective randomized phase III study of the EBMT (RICMAC Trial). J Clin Oncol Off J Am Soc Clin Oncol 35:2157\u20132164. https:\/\/doi.org\/10.1200\/JCO.2016.70.7349","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"6881_CR7","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","volume":"35","author":"BL Scott","year":"2017","unstructured":"Scott BL, Pasquini MC, Logan BR et al (2017) Myeloablative versus Reduced-Intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol Off J Am Soc Clin Oncol 35:1154\u20131161. https:\/\/doi.org\/10.1200\/JCO.2016.70.7091","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"6881_CR8","doi-asserted-by":"publisher","first-page":"483e1","DOI":"10.1016\/j.jtct.2021.02.031","volume":"27","author":"BL Scott","year":"2021","unstructured":"Scott BL, Pasquini MC, Fei M et al (2021) Myeloablative versus Reduced-Intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic Syndromes\u2014Long-Term Follow-Up of the BMT CTN 0901 clinical trial. Transpl Cell Ther 27:483e1. https:\/\/doi.org\/10.1016\/j.jtct.2021.02.031","journal-title":"Transpl Cell Ther"},{"key":"6881_CR9","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/cncr.27786","volume":"119","author":"D Blaise","year":"2013","unstructured":"Blaise D, Tabrizi R, Boher J et al (2013) Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen\u2010matched, related allogeneic peripheral blood stem cell transplantation: prospective clinical and socioeconomic evaluation. Cancer 119:602\u2013611. https:\/\/doi.org\/10.1002\/cncr.27786","journal-title":"Cancer"},{"key":"6881_CR10","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1016\/S2352-3026(19)30157-7","volume":"7","author":"DW Beelen","year":"2020","unstructured":"Beelen DW, Trenschel R, Stelljes M et al (2020) Treosulfan or Busulfan plus fludarabine as conditioning treatment before allogeneic Haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14\/L): a randomised, non-inferiority, phase 3 trial. Lancet Haematol 7:e28\u2013e39. https:\/\/doi.org\/10.1016\/S2352-3026(19)30157-7","journal-title":"Lancet Haematol"},{"key":"6881_CR11","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S1470-2045(15)00200-4","volume":"16","author":"A Rambaldi","year":"2015","unstructured":"Rambaldi A, Grassi A, Masciulli A et al (2015) Busulfan plus cyclophosphamide versus Busulfan plus fludarabine as a preparative regimen for allogeneic Haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 16:1525\u20131536. https:\/\/doi.org\/10.1016\/S1470-2045(15)00200-4","journal-title":"Lancet Oncol"},{"key":"6881_CR12","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1200\/JCO.20.02308","volume":"39","author":"C Craddock","year":"2021","unstructured":"Craddock C, Jackson A, Loke J et al (2021) Augmented Reduced-Intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia. J Clin Oncol 39:768\u2013778. https:\/\/doi.org\/10.1200\/JCO.20.02308","journal-title":"J Clin Oncol"},{"key":"6881_CR13","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41409-022-01871-8","volume":"58","author":"Y Shimomura","year":"2023","unstructured":"Shimomura Y, Komukai S, Kitamura T et al (2023) Identifying the optimal conditioning intensity for stem cell transplantation in patients with myelodysplastic syndrome: a machine learning analysis. Bone Marrow Transpl 58:186\u2013194. https:\/\/doi.org\/10.1038\/s41409-022-01871-8","journal-title":"Bone Marrow Transpl"},{"key":"6881_CR14","doi-asserted-by":"publisher","unstructured":"Huling JD, Yu M (2021) Subgroup identification using the personalized package. J Stat Softw 98. https:\/\/doi.org\/10.18637\/jss.v098.i05","DOI":"10.18637\/jss.v098.i05"},{"key":"6881_CR15","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/biom.12676","volume":"73","author":"S Chen","year":"2017","unstructured":"Chen S, Tian L, Cai T, Yu M (2017) A general statistical framework for subgroup identification and comparative treatment scoring. Biometrics 73:1199\u20131209. https:\/\/doi.org\/10.1111\/biom.12676","journal-title":"Biometrics"},{"key":"6881_CR16","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.bbmt.2019.09.025","volume":"26","author":"T Konuma","year":"2020","unstructured":"Konuma T, Kondo T, Mizuno S et al (2020) Conditioning intensity for allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients with Poor-Prognosis cytogenetics in first complete remission. Biol Blood Marrow Transpl 26:463\u2013471. https:\/\/doi.org\/10.1016\/j.bbmt.2019.09.025","journal-title":"Biol Blood Marrow Transpl"},{"key":"6881_CR17","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/bmt.2015.121","volume":"50","author":"JR Passweg","year":"2015","unstructured":"Passweg JR, Labopin M, Cornelissen J et al (2015) Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group\u2013an observational analysis by the acute leukemia working party of the EBMT. Bone Marrow Transpl 50:1063\u20131068. https:\/\/doi.org\/10.1038\/bmt.2015.121","journal-title":"Bone Marrow Transpl"},{"key":"6881_CR18","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1200\/JCO.19.03011","volume":"38","author":"CS Hourigan","year":"2020","unstructured":"Hourigan CS, Dillon LW, Gui G et al (2020) Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol Off J Am Soc Clin Oncol 38:1273\u20131283. https:\/\/doi.org\/10.1200\/JCO.19.03011","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"6881_CR19","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/ajh.25211","volume":"93","author":"MH Gilleece","year":"2018","unstructured":"Gilleece MH, Labopin M, Yakoub-Agha I et al (2018) Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the acute leukemia working party E. Am J Hematol 93:1142\u20131152. https:\/\/doi.org\/10.1002\/ajh.25211","journal-title":"Am J Hematol"},{"key":"6881_CR20","doi-asserted-by":"publisher","first-page":"680","DOI":"10.7326\/0003-4819-154-10-201105170-00008","volume":"154","author":"TJ VanderWeele","year":"2011","unstructured":"VanderWeele TJ, Knol MJ (2011) Interpretation of subgroup analyses in randomized trials: heterogeneity versus secondary interventions. Ann Intern Med 154:680\u2013683. https:\/\/doi.org\/10.7326\/0003-4819-154-10-201105170-00008","journal-title":"Ann Intern Med"},{"key":"6881_CR21","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/S2213-8587(17)30176-6","volume":"5","author":"A Baum","year":"2017","unstructured":"Baum A, Scarpa J, Bruzelius E et al (2017) Targeting weight loss interventions to reduce cardiovascular complications of type 2 diabetes: a machine learning-based post-hoc analysis of heterogeneous treatment effects in the look AHEAD trial. Lancet Diabetes Endocrinol 5:808\u2013815. https:\/\/doi.org\/10.1016\/S2213-8587(17)30176-6","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6881_CR22","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","volume":"15","author":"S Giralt","year":"2009","unstructured":"Giralt S, Ballen K, Rizzo D et al (2009) Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl 15:367\u2013369. https:\/\/doi.org\/10.1016\/j.bbmt.2008.12.497","journal-title":"Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl"},{"key":"6881_CR23","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D et al (2009) Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl 15:1628\u20131633. https:\/\/doi.org\/10.1016\/j.bbmt.2009.07.004","journal-title":"Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl"},{"key":"6881_CR24","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106:2912\u20132919. https:\/\/doi.org\/10.1182\/blood-2005-05-2004","journal-title":"Blood"},{"key":"6881_CR25","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/bioinformatics\/btr597","volume":"28","author":"DJ Stekhoven","year":"2012","unstructured":"Stekhoven DJ, B\u00fchlmann P (2012) MissForest\u2013non-parametric missing value imputation for mixed-type data. Bioinforma Oxf Engl 28:112\u2013118. https:\/\/doi.org\/10.1093\/bioinformatics\/btr597","journal-title":"Bioinforma Oxf Engl"},{"key":"6881_CR26","doi-asserted-by":"publisher","first-page":"e002847","DOI":"10.1136\/bmjopen-2013-002847","volume":"3","author":"AK Waljee","year":"2013","unstructured":"Waljee AK, Mukherjee A, Singal AG et al (2013) Comparison of imputation methods for missing laboratory data in medicine. BMJ Open 3:e002847. https:\/\/doi.org\/10.1136\/bmjopen-2013-002847","journal-title":"BMJ Open"},{"key":"6881_CR27","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1093\/aje\/kwj047","volume":"163","author":"T Kurth","year":"2006","unstructured":"Kurth T, Walker AM, Glynn RJ et al (2006) Results of multivariable logistic Regression, propensity Matching, propensity Adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 163:262\u2013270. https:\/\/doi.org\/10.1093\/aje\/kwj047","journal-title":"Am J Epidemiol"},{"key":"6881_CR28","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1200\/JCO.2014.59.1339","volume":"33","author":"R Shouval","year":"2015","unstructured":"Shouval R, Labopin M, Bondi O et al (2015) Prediction of allogeneic hematopoietic stem-cell transplantation mortality 100 days after transplantation using a machine learning algorithm: a European Group for Blood and Marrow Transplantation Acute Leukemia Working Party retrospective data mining study. J Clin Oncol Off J Am Soc Clin Oncol 33:3144\u20133151. https:\/\/doi.org\/10.1200\/JCO.2014.59.1339","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"6881_CR29","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.1182\/bloodadvances.2019000934","volume":"3","author":"Y Arai","year":"2019","unstructured":"Arai Y, Kondo T, Fuse K et al (2019) Using a machine learning algorithm to predict acute graft-versus-host disease following allogeneic transplantation. Blood Adv 3:3626\u20133634. https:\/\/doi.org\/10.1182\/bloodadvances.2019000934","journal-title":"Blood Adv"},{"key":"6881_CR30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.bbmt.2020.09.020","volume":"27","author":"B Dholaria","year":"2021","unstructured":"Dholaria B, Savani BN, Hamilton BK et al (2021) Hematopoietic cell transplantation in the treatment of newly diagnosed adult acute myeloid leukemia: an Evidence-Based review from the American society of transplantation and cellular therapy. Transpl Cell Ther 27:6\u201320. https:\/\/doi.org\/10.1016\/j.bbmt.2020.09.020","journal-title":"Transpl Cell Ther"},{"key":"6881_CR31","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.1182\/bloodadvances.2022008706","volume":"7","author":"Y Akahoshi","year":"2023","unstructured":"Akahoshi Y, Tada Y, Sakaida E et al (2023) Novel risk assessment for the intensity of conditioning regimen in older patients. Blood Adv 7:4738\u20134747. https:\/\/doi.org\/10.1182\/bloodadvances.2022008706","journal-title":"Blood Adv"},{"key":"6881_CR32","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1056\/NEJMoa1611604","volume":"376","author":"RC Lindsley","year":"2017","unstructured":"Lindsley RC, Saber W, Mar BG et al (2017) Prognostic mutations in myelodysplastic syndrome after Stem-Cell transplantation. N Engl J Med 376:536\u2013547. https:\/\/doi.org\/10.1056\/NEJMoa1611604","journal-title":"N Engl J Med"},{"key":"6881_CR33","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1038\/s41409-021-01217-w","volume":"56","author":"Y Shimomura","year":"2021","unstructured":"Shimomura Y, Hara M, Yamamoto H et al (2021) Adding Melphalan to fludarabine and a myeloablative dose of Busulfan improved survival after allogeneic hematopoietic stem cell transplantation in a propensity score-matched cohort of hematological malignancies. Bone Marrow Transpl 56:1691\u20131699. https:\/\/doi.org\/10.1038\/s41409-021-01217-w","journal-title":"Bone Marrow Transpl"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06881-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06881-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06881-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:58:26Z","timestamp":1776405506000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06881-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6881"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06881-w","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"19 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Data Management Committee of the JDCHCT and the Ethics Committee of Osaka University (approval number: 22143).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Patient consent was obtained before the TRUMP 2 registration.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient Concent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"124"}}